Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

Researchers Uncover Mechanism That Fuels Growth of Aggressive B-Cell Lymphoma June 18 ... A new detailed analysis of a patient's second cancer after receiving CAR-T therapy for the initial ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children ...

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).